Grant ID RP120727
Awarded On March 29, 2012
Title Development of a targeted therapy: a treatment that is able to suppress breast cancer initiating cells
Program Academic Research
Award Mechanism Bridging the Gap: Early Translational Research Awards
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Mien-Chie Hung
Cancer Sites Breast
Contracted Amount $999,872
Lay Summary

Tumor initiation cells (TICs, also known as cancer stems cells) are a small subpopulation of cells within the tumor that are highly aggressive and are suggested to be responsible for initiation of cancer and resistance to traditional cancer therapy. It has been reported that with conventional treatments, such as chemotherapy and radiotherapy, the percent of BTICs in the tumors increases from 9% to 74% after treatment, even though the overall tumor mass is reduced, making resistance to cancer treatment a major obstacle for breast cancer therapies. To our knowledge, there are no drugs that can effectively reduce breast tumor initiation cells (BTICs) in the clinic, although the EGFR/HER2 tyrosi...

Read More